

Providing answers for
cancer patients

curasight

Curasight A/S Interim report Q3 2025

In this document, the following definitions shall apply unless otherwise specified: "the Company" or "Curasight" refers to Curasight A/S, CVR no. 35249389.

The Company
CURASIGHT A/S
Ole Maaløes Vej 3
2200 København N
Tel.: 22 83 01 60
Registered office: København N
CVR no.: 35 24 93 89
Financial year: 01.01 - 31.12

Key figures and selected posts

Q3 (2025-07-01 – 2025-09-30)

- Gross loss amounted to kDKK -12,076 (kDKK -6,135)
- Operating loss amounted to kDKK -13,545 (kDKK -8,099)
- Loss before tax amounted to kDKK -14,262 (kDKK -8,523)
- Loss for the period amounted to kDKK -19,204 (kDKK -10,737)
- Total assets amounted to kDKK 33,202 (kDKK 25,778)
- Equity ratio amounted to 52.6% (51.6%)
- Earnings per share amounted to DKK -0.28 (DKK -0.35)

Q1-Q3 (2025-01-01 – 2025-09-30)

- Gross loss amounted to kDKK -34,475 (kDKK -22,521)
- Operating loss amounted to kDKK -38,765 (kDKK -28,443)
- Loss before tax amounted to kDKK -41,420 (kDKK -30,002)
- Loss for the period amounted to kDKK -24,408 (kDKK -18,729)
- Total assets amounted to kDKK 33,202 (kDKK 25,778)
- Equity ratio amounted to 52.6% (51.6%)
- Earnings per share amounted to DKK -0.81 (DKK -1.25)

Numbers in parenthesis are the numbers from the same period in 2024.

Definitions
Equity ratio: Shareholders equity as a proportion of total assets.
Earnings per share: Profit/Loss for the period divided by average number of shares.

Progressing our ambition for treatment of brain cancer

During the third quarter of 2025 and period after, Curasight continued to make significant clinical and strategic progress as we advance our mission to improve outcomes for patients with serious cancers through precision diagnostics and targeted radionuclide therapy. Our pipeline is moving forward on several key fronts, and we are particularly pleased that we are ready for recruitment in our first clinical trial with uTREAT®. The Phase 1 study in brain cancer has now gained all the necessary approvals to be able to start treating patients and we remain on track to dose the first patient and to report initial biodistribution data before the end of this year. We also continue to strengthen our intellectual property position and maintain momentum in our uTRACE® phase II trial.

Initiating the Phase 1 study investigating uTREAT for brain cancer has been a large focus of our work over the last few months. This study represents an important milestone for Curasight, marking the clinical debut of our therapeutic ligand as we expand from diagnostics to targeted radionuclide therapy. We very much look forward to announcing the dosing of the first patient once that has taken place.

In line with our strategy for parallel development of both treatment and diagnosis, we also continued to advance our uTRACE® program in prostate cancer. All European clinical sites participating in Part 2 of the ongoing Phase 2 trial investigating our diagnostic platform are now actively recruiting patients. The expansion of recruitment was an important operational achievement and brings us closer to generating the data needed to further validate

uTRACE® as a highly precise imaging tool for improved patient stratification and treatment planning.

In parallel with this clinical progress, at the start of October we announced the strengthening of our intellectual property portfolio. The broadening and extension of patent protection for uTRACE® provides Curasight with increased long-term security around a core component of our platform. This enhanced protection supports our commercial strategy while reinforcing the value of uTRACE® as a differentiated and defensible asset in the global oncology landscape.

Looking ahead, our focus remains on disciplined execution across all programs. As we work towards the dosing of the first patient in our uTREAT® Phase 1 study we continue to focus on ensuring active recruitment across our uTRACE® prostate cancer Phase II study. With the expanded IP foundation announced recently we believe Curasight is well positioned to deliver meaningful clinical and corporate milestones in the months ahead.

I would like to thank our employees, investigators, patients, and partners for their continued commitment. Their contributions are essential as we advance our vision of transforming cancer care through precision-targeted radiopharmaceuticals.

Sincerely,

Ulrich Krasilnikoff
CEO, Curasight A/S


Highlights during third quarter and after the peiord

On August 26, announced that the European Medicines Agency (EMA) has approved the company's clinical trial application (CTA) for the investigation of uTREAT® in a phase 1 trial.

On October 1, announced issuance of US patent 12,409,240 B2 which expands the protection of the company's uPAR diagnostic platform, uTRACE. The patent term has been extended by 751 days (more than 2 years) so that it now expires in 2035.

On October 29, announced strong momentum in part 2 of the Phase 2 Study as all nine sites across Germany, Sweden and Denmark are now fully activated and recruiting patients.

On November 26, announced that its phase 1 trial investigating uTREAT® for aggressive brain cancer is now open for patient enrollment.

A photograph of an older woman with short, light-colored hair, smiling broadly while jogging. She is wearing a light gray sleeveless top and a white wristband. In the background, slightly out of focus, is a man with gray hair wearing a dark blue t-shirt, also jogging. They are outdoors on a paved path with green trees in the background.

By combining diagnostics with therapy – Curasight is on a mission to improve the lives of millions of people with cancer

Curasight A/S in short

Curasight is a clinical phase II company based in Copenhagen, Denmark. Curasight is the pioneer behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy with the precise uTRACE® diagnostics. Several investigator-initiated phase II clinical trials have been completed or are currently undertaken.


PET-imaging, usually combined with CT as PET/CT is used to create images in which the biology of the disease can be studied. The principle is that a radiolabelled tracer is injected and bound to the tumor targets in the tissues, e.g. uPAR, after which the radioactivity can be located with the help of a PET-scanner. Together with his team, Professor Andreas Kjaer, developed a platform based on the radiolabelled PET-tracer uTRACE®, Curasight's novel product that highlights the cancer biomarker uPAR. By injecting the patient with uTRACE®, one can both image where the cancer is located and determine its level of aggressiveness.

uTRACE images cancer aggressiveness and invasive potential. By imaging this, Curasight's technology can diagnose and determine which therapeutic strategy should be pursued, e.g. if the patient needs treatment (e.g. surgery such as prostatectomy and/or radiotherapy) or not. In addition, uTRACE® will be used for theranostics (principle of combined therapy and diagnostics) and precision medicine, selecting the right therapy to the right person at the right time, creating substantial benefits for both patients and the healthcare system.

uTRACE solution is expected to have major advantages in the future evaluation of prostate cancer because it is expected to help determine what type of treatment – and in particular if surgery – is necessary. Today most prostate cancer patients having prostatectomies performed are operated unnecessarily and most of these patients (up to 70 percent) experience some degree of side effects, such as impotence. The company believes that using Curasight's product and diagnosis could improve patient management. uTRACE® is designed to provide a more accurate categorisation of a patient's tumor, supporting more tailored treatment plans allowing which can identify the necessary treatment at the right time.

Curasight's technology has been tested in phase II academic clinical trials. According to the board's assessments, there is currently no other early-stage biotech company in the field of PET tracer development that has their technology tested in a broader portfolio of

ongoing and planned clinical trials in humans (whether investigator-initiated and academically sponsored or industry-sponsored trials), in many different cancer indications. In 2017 a phase I/IIa first-in-human academic clinical trial with uTRACE® was completed. In 2018 a phase IIb academic clinical trial with uTRACE® in breast cancer; in 2020 a phase II academic study in prostate cancer in 2021/2022 two academic studies in head-and-neck cancer and neuroendocrine tumors, respectively, were completed, and in 2023 the study in brain cancer was completed. A study in lung cancer is ongoing.



Targeted radionuclide therapy (theranostics) is expected to be the radiation therapy of the future. With the promising results obtained within diagnostics, Curasight now also pursues uPAR targeted radionuclide therapy using the uTRACE® ligand but "armed" with short-range (1 mm) radiation therapy. In brief, the therapeutic ligand will be injected into a vein after which it will circulate and bind to all cancer cells in the body expressing uPAR and locally irradiate cancer with limited irradiation of healthy tissue. This concept represents a gentler form of radiotherapy compared to traditional external radiation therapy and is therefore by many considered the "radiation therapy of tomorrow". As PET imaging and radionuclide therapy are based on the same uPAR binding peptide, a uTRACE®-scan can precisely predict where subsequent targeted radiation therapy will be delivered (theranostic principle).

Business model and critical path to regulatory approval

Curasight aims to establish its theranostic approach using imaging targeting the uPAR protein to improve the diagnosis and treatment of selective cancers. The company's uTRACE® platform can be used as an alternative to biopsies to discover and characterise tumors and the uTREAT® platform can then be used for more targeted treatment of the tumor.

Currently Curasight is focused on generating data with both uTRACE® and uTREAT® in cancers including prostate cancer and glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non small cell lung cancer (NSCLC), and pancreatic cancer. Each of these cancers offer different development opportunities and it is Curasight's aim, based on clinical data, to find experienced partners who can collaborate on the later stages of development of uTRACE® and uTREAT®. Currently Curasight has a partnership for uTRACE® in prostate cancer with Curium, a leader in the field of radionuclide medicine.

Additionally, as a small and nimble company, Curasight seeks out highly specialised partners to support its operational drug development, for example with research and clinical contract organisations who are highly competent in the field of both diagnostic and therapeutic radiopharmaceuticals. By forming partnerships with Contract Development Manufacturing Organisations (CDMOs), and Clinical Research Organisations (CROs) we ensure access to top development manufacturing expertise and capacity and skills in conducting manufacturing of investigational medicine and clinical trials in accordance with good manufacturing (GMP) and clinical practice (GCP). We have now signed an agreement with Minerva Imaging ApS considered to be the optimal CDMO for the manufacture of the Investigational Medicinal Product for our coming clinical study with uTRACE®. Likewise, we have finalised the contract with the CRO partner for our upcoming Phase 2 trial in prostate cancer with a 64Cu-labeled version of uTRACE®.

Outlook for Curasight

Curasight is expanding and accelerating its clinical therapeutic strategy with the addition of a new Phase I/IIa trial in brain cancer (Glioblastoma) to demonstrate clinical "proof-of-concept" for uTREAT®. A route has been identified with the aim to pursue a single indication for a relatively small trial that can be completed rapidly to provide this first validation of uTREAT®. As the uPAR-biomarker is cancer specific but not cancer type specific it works across cancer types, we can document the efficacy and safety in a cost effective and rapid way

in a first indication and then run the larger and more complex basket study with five different indications to provide further broader evidence of the application in different cancer types. The plan is to enroll the first patient in Q4 2025.

After completion a first Phase I/IIa study with uTREAT® in a single indication, high grade glioma, Curasight plans to expand and accelerate its clinical therapeutic strategy with the addition of a Phase II basket trial to include a total of five cancer indications in the same trial. The trial will investigate Curasight's theranostic approach by testing the diagnosis platform uTRACE® and treatment platform uTREAT® in:

- Neuroendocrine tumors (NET)
- Head and Neck cancer
- Non-Small Cell Lung cancers (NSCLC), and
- Pancreatic cancer.

The new Phase II basket trial will apply Curasight's uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®) and expect to initiate this trial in 2026. Curasight is committed to accelerating the development of its uTREAT® therapeutic platform in order to develop both uTREAT® and its diagnosis platform uTRACE® in parallel, to deliver better options to patients with certain types of cancer. By launching this basket trial Curasight can accelerate and broaden the development of both uTRACE® and uTREAT®, providing validation for potential partners of the use of our theranostic platform.

Furthermore, Curasight is looking into how to unfold further our platform and how to broaden the mission to realize the vast potential of uTRACE® for diagnosing and uTREAT® for targeted radionuclide therapy in other cancer types where uPAR is also expressed.

About high grade glioma and glioblastoma

Treatment of glioblastoma presents a significant unmet medical need, necessitating innovative and effective treatments. Curasight's research and development efforts aim to address this challenge and improve the lives of patients facing aggressive brain cancer. Curasight's first goal is to advance its lead platforms uTREAT® (used for therapy) and uTRACE® (used for diagnosing) to improve outcomes for the approx. 65,000 patients in the US and EU diagnosed annually with brain tumours. Accordingly, approximately 30,000 patients are diagnosed each year with high-grade glioma where the prognosis is very poor. Glioblastoma is a rare disease in both markets, qualifying for Orphan Drug Designation; moreover, because of the high unmet need, platforms targeting it are more likely to qualify for e.g. Priority Review, Breakthrough Therapy Designation,

or Accelerated Approval. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50 % of the patients die within 14 months and after five years from diagnosis only 5 % are still alive.

About neuroendocrine tumors

Each year approximately 35,000 new cases are diagnosed in the US and EU. Due to the long survival of these patients, more than 400,000 patients are living with the disease in the US and EU. Neuroendocrine tumors are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body. The main findings from the phase II trial with uTRACE® were that uPAR-positive lesions were seen in most NET patients and that uPAR PET was prognostic, and that uPAR will be a promising target for therapy in NET patients.

About head and neck cancer

Head and neck squamous cell carcinoma is the 6th most common cancer worldwide with 890,000 new cases and 450,000 deaths in 2018. The incidence is anticipated to increase over the coming years. The main finding from the Phase II trial using uTRACE® was that patients with high uptake on uPAR-PET compared to those with a low uptake had an 8.5-fold poorer prognosis regarding relapse-free survival. The conclusion from the trial was that uPAR-PET could become valuable regarding planning of therapy and follow-up in head and neck cancer patients. In addition, the presence of uPAR in head and neck cancer patients and in particular, in those with the most aggressive disease, also formed the basis for pursuing uPAR-targeted radionuclide therapy (uTREAT®) in this cancer type.

About Non Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. NSCLC is the most common type of lung cancer with approximately 700,000 patients being diagnosed each year in the US and EU alone. The 5-year survival rate in the US is around 28 %. Despite advances, there is a need for more effective therapies. Curasight's preclinical studies show uTREAT® effective in treating non-small cell lung cancer (NSCLC). Preliminary data from the investigator-initiated study presented at WMIC in Prague last year, demonstrates that almost all NSCLC tumors are uPAR positive and thus would be eligible for uTREAT®.

About Pancreatic Cancer

Pancreatic cancer is the 12th most common cancer worldwide. It is the 12th most common cancer in men and the 11th most common cancer in women. There were more than 495,000 new cases of pancreatic cancer in 2020. Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It makes enzymes that help digestion and hormones that control blood-sugar levels. More than 66,000 Americans are expected to be diagnosed with pancreatic cancer in 2024.

About Prostate cancer


Prostate cancer is the most common cancer in men, with approximately 640,000 new cases expected to be diagnosed annually across the US and the EU. While many tumors grow slowly, a significant proportion develop into aggressive disease that is challenging to detect and monitor with existing methods. Accurate detection and monitoring of prostate cancer remain major challenges, particularly in patients with advanced or recurrent disease. Current diagnostic methods often lack precision in identifying aggressive tumors and assessing disease progression. Curasight's uTRACE technology is designed to address these challenges by targeting the uPAR biomarker, which is highly expressed in prostate cancer. By enabling more precise imaging, uTRACE has the potential to improve diagnosis, guide treatment decisions, and ultimately enhance outcomes for patients with prostate cancer.

Strategic partnerships

Due to the very encouraging results from the finalised investigator-initiated clinical phase-II study in Prostate Cancer, Curasight has entered into a collaborative partnership with Curium to accelerate the product development of uTRACE® as a more flexible and non-invasive risk stratification tool compared to the present gold standard (biopsy), for prostate cancer patients entering or being followed in active surveillance programs. The first milestone payment Curium has been received by us.

To support and accelerate the strategic business development, discussions are currently ongoing with a number of major pharma companies with a view to uncover opportunities and interest in uTRACE® and uTREAT®.

Key clinical milestones 2025-2026





Therapeutic Program

Pre-clinical

Phase I

Phase II

Phase III

Sponsor: Curasight**Diagnostic platform:** uTRACE® and uTREAT®

GBM

Glioblastoma (Brain cancer)

Phase I/IIa trial -
CTA submittedPhase IIb/III to
be planned

NSCLC

Non-Small Cell Lung cancers

NEN

Neuroendocrine neoplasms

HNSCC

Head & Neck Cancer

PaC

Pancreatic cancer

Completed

Phase I/IIa trial in
planning
Basket trial* across
selected cancer diseases

Applying the
theranostic approach
Combining diagnostic
(uTrace) and therapy
(uTreat)

Phase IIb/III to
be planned

*A basket trial is designed to simultaneously evaluate treatments for multiple tumors in a single clinical trial. Curasight will investigate cancer therapy with uTREAT® in selected cancer diseases known to express uPAR.



Partnered Project

Pre-clinical

Phase I

Phase II

Phase III

Sponsor: Curasight**Partner:** Curium Inc.**Diagnostic platform:** uTRACE®

Prostate Cancer*

Completed**

Ongoing

Planned

*) Investigated for diagnostic performance for non-invasive classification of ISUP grades among patients with localised, untreated prostate cancer.

**) Investigator-initiated study



Investigator Initiated Trials

Pre-clinical

Phase I

Phase II

Phase III

Sponsor: National University Hospital of Denmark (Rigshospitalet)**Diagnostic platform:** uTRACE®

GBM

Glioblastoma (Brain cancer)

Completed

PCa

Prostate cancer

Completed

NEN

Neuroendocrine neoplasms

Completed

HNSCC

Head & Neck Cancer

Completed

NSCLC

Non-Small Cell Lung cancer

Ongoing

BC

Breast cancer

Completed

UBC

Urinary bladder cancer

Completed**

Results from
uTRACE® IITs are used
as supportive data
in ongoing partner
project with Curium as
well as in potential future
partnering projects
and in the planning
of our therapeutic
program with a
theranostic
approach.

*) Investigator Initiated Trials = IITs, >400 patients have received utrache in these Investigator Initiated Trials

**) Completed with fewer patients than planned for technical reasons

Financial analyst coverage



Since:
June, 2021

Type:
Commissioned

Frequency:
Continuously

Areas:
Curasight's operations, platforms, markets and competitors

→ Read more



Since:
May, 2025

Type:
Commissioned

Frequency:
Continuously

Areas:
Curasight's operations, platforms, markets and competitors

→ Read more



Since:
August, 2021

Type:
Commissioned

Frequency:
Continuously

Areas:
Curasight's operations, platforms, markets and competitors

→ Read more

Corporate Information

Shareholders

The table below presents the management's shareholdings in Curasight.

Name	Votes & capital (%)
AK 2014 Holding ApS ¹	15,96
UK Curacap ApS ²	11,62
CHN Holding ApS ³	5,25
Madsen Holding 2013 ApS ⁴	2,04
LT 2003 ApS ⁵	1,29
Charlotte Vedel ⁶	0,17
Kirsten Drejer ⁷	0,08
Hanne Damgaard Jensen ⁸	0,12

1. Owned by co-founder, CSO, and Board Member Andreas Kjaer
2. Owned by CEO and Board Member Ulrich Krasilnikoff
3. Owned by co-founder Carsten H Nielsen
4. Owned by Co-founder and Director CMC, Jacob Madsen
5. Owned by Deputy Chairman of the Board, Lars Trolle
6. Member of the Board of Directors
7. Chair of the Board of Directors
8. COO

The share

The shares of Curasight A/S were listed on Spotlight Stock Market on October 8, 2020. The short name/ticker is CURAS, and the ISIN code is DK0061295797. As of September 30, 2025, the number of shares was 45,867,511 (20,682,427). All shares have equal rights to the Company's assets and results.

Long-term incentive program

Curasight has a long-term incentive program covering the financial years 2022-2025 with a total of 956,770 warrants covering the Company's Board of Directors, Executive Management and other key employees. For the Board of Directors, a total of 229,230 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 11,461.50 nominally worth of shares in the Company. The warrants are allocated between Lars Trolle (dept. chairman of the Board of Directors), Charlotte Vedel (member of the Board of Directors) and Kirsten Aarup Drejer (Chair of the Board of Directors).

For the Executive Management and other key employees of the Company, a total of 727,540 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 36,377.00 nominally worth of shares in the Company. The warrants are allocated between Ulrich Krasilnikoff (CEO), Andreas Kjaer (CSO), Hanne Damgaard Jensen (CDO), Nic Gillings (Head of Quality Assurance and Regulatory Affairs) and Jacob Madsen (Director CMC).

On July 30, 2024, Curasight re-issued a total of 59,132 (previously lapsed) warrants with rights to subscribe for a total of DKK 2,956.60 nominally worth of shares in the Company. 42,460 warrants will be re-issued as part of the ordinary incentive program covering the Executive Management and key employees of the Company. 16,672 warrants will be re-issued and allocated to Chair of the Board of Directors Kirsten Drejer as part of the ordinary incentive program covering the Board of Directors of the Company.

Risks

A number of risk factors can affect Curasight's operations. It is therefore of great importance to consider relevant risks in addition to the Company's growth opportunities. For a detailed description of the risks attributable to the Company and its shares, please refer to the disclosure document published by the Company in 2025. The document is available on Curasight's website: www.curasight.com/investor/rights-issue-2025.

Accounting policy

The interim report is presented in accordance with the provisions of the Danish Financial Statements Act (Årsregnskabsloven) for enterprises in reporting class B with application of provisions for a higher reporting class.

Auditor's review

The interim report has not been reviewed by the Company's auditor.

Financial calendar	
Year-end report 2025	February 26, 2026
Annual report 2025	February 26, 2026
Interim report Q1 2026	April 23, 2026
Interim report Q2 2026	August 27, 2026
Interim report Q3 2026	November 26, 2026

Financial statements

Income statement

Operating loss before tax for the third quarter of 2025 amounted to kDKK -13,545 (kDKK -8,099). Operating loss before tax for the first nine months of 2025 amounted to kDKK -38,765 (kDKK -28,443).

Loss before depreciation, amortisation and impairments for the third quarter amounted to kDKK -13,341 (kDKK -7,895) of which staff expenses was kDKK -1,266 (kDKK -1,760). Loss before depreciation, amortisation and impairments for the first nine months of 2025 amounted to kDKK -38,154 (kDKK -27,833) of which staff expenses was kDKK -3,680 (kDKK -5,312).

Loss before depreciation, amortisation and impairments comprise of revenue, clinical expenses, patent expenses, staff expenses and other business expenses.

Balance sheet

Per September 30, 2025, the Company's balance sheet amounted to kDKK 33,202 (25,778).

The assets consisted primarily of acquired IP-rights totaling kDKK 6,217 related to the development of uTRACE® and uTREAT®, total receivables of kDKK 11,036 and cash amounted to kDKK 15,898. The equity and liabilities consisted primarily of an equity totaling kDKK 17,471 and short-term debt of kDKK 15,731.

Cash flow

Curasight's total cash flow in Q3 2025 amounted to kDKK -13,550. Curasight's cash flow from operating activities in July – September 2025 amounted to kDKK -13,550.

Cash as of September 30, 2025, was kDKK 15,898 (kDKK 7,983).



Income statement

(kDKK)	Q3 2025*	Q3 2024*	Q1-Q3 2025*	Q1-Q3 2024*	Q1-Q4 2024
Gross loss	-12,076	-6,135	-34,475	-22,521	-32,731
Staff expenses	-1,266	-1,760	-3,680	-5,312	-6,822
Loss before depreciation, amortisation, write-downs and impairment losses	-13,341	-7,895	-38,154	-27,833	-39,553
Depreciation, amortisation and impairment of intangible assets and property, plant and equipment	-204	-204	-611	-611	-814
Operating loss	-13,545	-8,099	-38,765	-28,443	-40,367
Net financial expenses	-717	-425	-2,655	-1,559	-1,969
Loss before tax	-14,262	-8,523	-41,420	-30,002	-42,336
Tax on loss for the period	1,375	1,375	4,125	4,125	4,125
Loss for the period	-12,887	-7,148	-37,295	-25,877	-38,211

*) Unaudited figures

Balance sheet, Assets

(kDKK)	2025-09-30*	2024-09-30*	2024-12-31
Acquired patents	6,217	7,031	6,827
Intangible assets	6,217	7,031	6,827
Deposits	51	51	51
Total investments	51	51	51
Total non-current assets	6,268	7,082	6,878
Other receivables	1,411	1,134	1,299
Income tax receivables	9,625	9,625	4,125
Total receivables	11,036	10,759	5,424
Cash at bank and in hand	15,898	7,938	10,011
Total current assets	26,934	18,697	15,435
Assets	33,202	25,778	22,314

*) Unaudited figures

Balance sheet—Liabilities and equity

(kDKK)	2025-09-30	2024-09-30	2024-12-31
Share capital	2,293	1,034	1,057
Retained earnings	15,177	12,271	5,279
Equity	17,471	13,305	6,336
Trade payables	5,737	1,866	4,155
Other payables	9,994	201	11,823
Debt	0	10,406	0
Short term-debt	15,731	12,473	15,978
Debt	15,731	12,473	15,978
Liabilities and equity	33,202	25,778	22,314

Equity—Q3* 2025

(kDKK)				
Change in equity Q3 2025	Share capital	Share account premium	Retained earnings	Total
Equity at 1 July 2025	2,293	13,125	14,885	30,303
Net profit/loss for the year	0	54	-12,887	-12,833
Equity at 30 September 2025	2,293	13,179	1,999	17,471

*) Unaudited figures

Equity—Q3* 2024

(kDKK)				
Change in equity: Q3 2024	Share capital	Share account premium	Retained earnings	Total
Equity at 1 July 2024	995	0	11,659	12,654
Net profit/loss for the period	0	0	-7,148	-7,148
Capital Increase	39	0	7,761	7,800
Equity at 30 September 2024	1,034	0	12,271	13,305

Equity—FY 2024

(kDKK)			
Change in equity: Q1-Q4 2024	Share capital	Retained earnings	Total
Equity at 1 January 2024	995	30,388	31,383
Net profit/loss for the year	0	-38,211	-38,211
Capital Increase	62	13,102	13,164
Equity at 31 December 2024	1,057	5,279	6,336

*) Unaudited figures

Equity—Q1-Q3* 2025

(kDKK)				
Change in equity Q1-Q3 2025	Share capital	Share account premium	Retained earnings	Total
Equity at 1 January 2025	1,057	0	5,279	6,336
Net profit/loss for the year	1,236	13,179	-3,280	11,135
Equity at 30 September 2025	2,293	13,179	1,999	17,471

*) Unaudited figures

Equity—Q1-Q3* 2024

(kDKK)				
Change in equity: Q1-Q3 2024	Share capital	Share account premium	Retained earnings	Total
Equity at 1 January 2024	995	0	30,388	31,383
Net profit/loss for the year	0	0	-25,877	-25,877
Net profit/loss for the year	39	0	7,761	7,800
Equity at 30 September 2024	1,034	0	12,271	13,305

Cash flow statement

(kDKK)	Q3 2025*	Q3 2024*	Q1-Q3 2025*	Q1-Q3 2024*	Q1-Q4 2024
Loss for the period	-12,887	-7,148	-37,295	-25,877	-38,211
Adjustments	-1,459	253	-2,319	-1,955	-1,342
Change in working capital	-479	-1,232	-1,809	-957	944
Cash flow from operating activities before net financials	-14,825	-8,127	-43,231	-28,789	-38,609
Interest expenses and similar expenses paid	-100	-119	-2,285	-1,153	-1,046
Income tax received/paid	1,375	0	4,125	0	5,500
Cash flow from operating activities	-13,550	-8,246	-41,391	-29,942	-34,156
Proceeds from loans	0	0	0	10,000	10,922
Capital increase	0	7,800	47,279	7,800	13,164
Cash flows from investing activities	0	7,800	47,279	17,800	24,086
Total cash flows for the period	-13,550	-446	5,888	-12,142	-10,069
Cash, beginning of the period	29,449	8,384	10,011	20,080	20,080
Cash, end of the period	15,899	7,938	15,898	7,938	10,011
Cash, end of the period	15,899	7,938	15,898	7,938	10,011
Total	15,899	7,938	15,898	7,938	10,011

*) Unaudited figures

Statement by the Board of Directors

The Board of Directors provide their assurance that the interim report provides a fair and true overview of the Company's operations, financial position, and results.

København N, November 27, 2025
Curasight A/S

Board of Directors

Kirsten Drejer
Chair of the Board

Lars Trolle
Dept. chair of the Board

Charlotte Vedel
Board member

Andreas Kjær
Board member

Ulrich Krasilnikoff
Board member and CEO

Curasight's team are pioneers behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT[®] radiation therapy, with the precise uTRACE[®] diagnostics.